Werewolf Therapeutics is a clinical-stage biopharmaceutical company that has moved away from active drug development and into a broader strategic review. Without approved products, its quarterly results focus mainly on cost control, cash management, and the progress of corporate transactions. The Q3 2026 numbers arrive during a pivotal stretch: the company sold its JZP898 program to Jazz Pharmaceuticals, divested its preclinical INDUKINE and INDUCER platforms to EMD Serono, and entered an all-stock merger agreement with Ambros Therapeutics. For investors, this release serves as a progress report on capital conservation and whether the going-concern risk is being mitigated ahead of the merger vote.
For the third quarter ended September 30, 2026, HOWL posted a net loss of $9.9 million, improved from the $16.4 million loss in the year-ago quarter. Net loss per share came in at $0.20, better than both the prior-year figure of $0.36 and the $0.22 consensus estimate. No collaboration revenue was recognized in the quarter. Over the first nine months of 2026, the company recorded $21.0 million in collaboration revenue from the JZP898 sale. Total operating expenses dropped to $10.1 million from $15.7 million, led by a sharp reduction in R&D spending to $2.2 million from $11.6 million. G&A expenses increased to $7.9 million from $4.1 million, largely due to higher professional fees tied to the strategic review and merger work. Cash and cash equivalents totaled $41.9 million at quarter end, down from $57.1 million at the end of 2025, and the company again flagged substantial doubt about continuing as a going concern without the merger.
HOWL shares have moved within a wide range over the past year and continue to face delisting risk after missing Nasdaq’s $1.00 minimum bid price. Sentiment centers less on the quarterly results and more on the pending merger with Ambros Therapeutics, which would make Werewolf a subsidiary while issuing non-transferable contingent value rights linked to the legacy WTX-124 and WTX-330 programs. The modest earnings beat is unlikely to drive the stock by itself; investors are focused on the probability of deal completion and any potential value from the CVRs. The going-concern disclosure and dependence on the merger remain the key risk factors.
The immediate priority is the special stockholder meeting set for December 17, 2026, where shareholders will vote on the Ambros Therapeutics merger. Completion still depends on closing conditions, and the company has noted that its ability to operate hinges on finishing the transaction on schedule. Investors should also track recognition of income from the EMD Serono sale: Werewolf received $28.9 million in non-refundable proceeds and expects to recognize the full $33.9 million transaction price as income in Q4 2026 once acceptance is confirmed. On the clinical side, data for WTX-124 and WTX-330 were presented at the Society for Immunotherapy of Cancer’s 2026 Annual Meeting, with both trials completed in Q4. Any further development of these assets will require new funding, and their value would flow through the CVR structure if the merger occurs. Additional items to monitor include the Nasdaq compliance deadline of February 1, 2027, and further details on restructuring costs and cash runway.
When reviewing names like HOWL in the biotechnology space, I often turn to Tickeron’s AI Screener to quickly compare fundamentals, technical patterns, and performance metrics across the sector. It helps surface relevant peers and highlight any standout signals without manual effort. This kind of tool fits naturally into my workflow when evaluating smaller companies navigating major corporate events.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
HOWL moved above its 50-day moving average on November 16, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where HOWL advanced for three days, in 204 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 118 of 137 cases where HOWL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
The 10-day RSI Indicator for HOWL moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 20 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HOWL as a result. In 68 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for HOWL turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 37 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HOWL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
HOWL broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. HOWL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.013) is normal, around the industry mean (3.586). P/E Ratio (-1.403) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.169) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HOWL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology